Clinical trials
Triple Negative Breast Neoplasms trials in Germany
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
62 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2011 | 2 |
| 2012 | 2 |
| 2013 | 2 |
| 2014 | 1 |
| 2015 | 2 |
| 2016 | 5 |
| 2017 | 8 |
| 2018 | 7 |
| 2019 | 4 |
| 2020 | 5 |
| 2021 | 4 |
| 2022 | 6 |
| 2023 | 1 |
| 2024 | 7 |
| 2025 | 5 |
| 2026 | 1 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Completed | 28 |
| Recruiting | 14 |
| Active, not recruiting | 10 |
| Terminated | 7 |
| Not yet recruiting | 3 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Novartis Pharmaceuticals | 12 |
| Merck Sharp & Dohme LLC | 7 |
| Hoffmann-La Roche | 6 |
| Bristol-Myers Squibb | 3 |
| Gilead Sciences | 3 |
| Seagen, a wholly owned subsidiary of Pfizer | 3 |
| AbbVie | 2 |
| GBG Forschungs GmbH | 2 |
| Women's Cancer Study Group GmbH | 2 |
| AVEO Pharmaceuticals, Inc. | 1 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Triple Negative Breast Neoplasms | 62 |
| Breast Neoplasms | 19 |
| Carcinoma, Non-Small-Cell Lung | 17 |
| Colorectal Neoplasms | 12 |
| Melanoma | 10 |
| Ovarian Neoplasms | 8 |
| Carcinoma, Renal Cell | 6 |
| Endometrial Neoplasms | 6 |
| Pancreatic Neoplasms | 6 |
| Squamous Cell Carcinoma of Head and Neck | 6 |
Trials
Showing 76 to 62 of 62. Each trial links to its page on Pharma Observatory.
No trials match these filters.
Try a different keyword, or clear a filter.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.